Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Florida Pulmonary Group P.A.

Neither a doctor nor a teaching hospital

Research payments

$824,368

18 payments

Through program year 2025, Central Florida Pulmonary Group P.A. is reported as receiving $824,368 in research payments, across 18 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$147,055	3
2024	Research	$78,484	3
2023	Research	$270,882	3
2021	Research	$45,801	2
2020	Research	$282,146	7

Breakdown

Who paid Research payments · program years 2020–2025

Vertex Pharmaceuticals Incorporated $824,368 18 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks $267,553 3 payments
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis $118,573 1 payment
A Phase 1 Study of VX-814 $71,748 1 payment
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype $61,315 2 payments
A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668 $60,166 2 payments
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy $56,382 1 payment
A Phase 4 Decentralized Pilot Study With Wearable Technology in Cystic Fibrosis Subjects 18 Years of Age and Older Taking Commercial Elexacaftor/Tezacaftor/Ivacaftor $39,369 1 payment
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) $33,698 1 payment
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy $32,430 1 payment
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype $27,789 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.